Kenneth Rockwood MD MPA FRCPC is Professor, Division of Geriatric Medicine, Department of Medicine and Kathryn Allen Weldon Professor of Alzheimer Research, Dalhousie University, Halifax NS, Canada. Serge Gauthier MD FRCPC is Professor and Director of the Alzheimer’s Disease Research Unit, The McGill Centre for Studies in Aging (Le Centre McGill D’Études sur le Vieillissement), Douglas Hospital, Montréal PQ, Canada.

"…a thorough and thoughtful examination of a complex area….a milestone in describing the playing field upon which drug trials of Alzheimer's disease should be conducted. It is a testament to how all the measures used to diagnose Alzheimer's disease do not equally gauge the progression of the disease. Alzheimer's disease is not monolithic, but varies greatly from stage to stage. This book promotes new ways of approaching this aspect of the disease."-Doody's Reviews

• Introduction. The History of Therapeutic Trials in Dementia. Therapeutic Strategies. Treatment Hypotheses. Clinical Trial Designs & Selection of Primary vs.Secondary Endpoints. Qualitative Analyses of Disease Treatment Effects. Inclusion and Exclusion Criteria. Global Outcomes. Cognitive Outcomes. Functional Outcomes. Behavioral Outcomes In Trials Of Cognitive Agents. Quality of Life Outcomes. Caregiver Burden Outcomes. Neuroimaging Outcomes. Additional Lessons From Trials in Vascular Dementia. Additional Lessons From Trials In Dementia With Lewy Bodies. Lessons From Trials To Prevent Dementia. Herbal Treatments for Dementia. Lessons from Trials of Psychoactive Compounds in Alzheimer's Disease. Lessons from Non-Pharmacologic and Psychosocial Interventions for Patients with Dementia. Lessons from Psychosocial Interventions Aimed at Caregivers of People with Dementia. Lessons from Trials in Mild Cognitive Impairment. Pharmacoeconomic Outcomes. Executive Dysfunction in Dementia. Ethical Issues. Conclusions.

Kenneth Rockwood MD MPA FRCPC is Professor, Division of Geriatric Medicine, Department of Medicine and Kathryn Allen Weldon Professor of Alzheimer Research, Dalhousie University, Halifax NS, Canada. Serge Gauthier MD FRCPC is Professor and Director of the Alzheimer’s Disease Research Unit, The McGill Centre for Studies in Aging (Le Centre McGill D’Études sur le Vieillissement), Douglas Hospital, Montréal PQ, Canada.

"…a thorough and thoughtful examination of a complex area….a milestone in describing the playing field upon which drug trials of Alzheimer's disease should be conducted. It is a testament to how all the measures used to diagnose Alzheimer's disease do not equally gauge the progression of the disease. Alzheimer's disease is not monolithic, but varies greatly from stage to stage. This book promotes new ways of approaching this aspect of the disease."-Doody's Reviews

• Introduction. The History of Therapeutic Trials in Dementia. Therapeutic Strategies. Treatment Hypotheses. Clinical Trial Designs & Selection of Primary vs.Secondary Endpoints. Qualitative Analyses of Disease Treatment Effects. Inclusion and Exclusion Criteria. Global Outcomes. Cognitive Outcomes. Functional Outcomes. Behavioral Outcomes In Trials Of Cognitive Agents. Quality of Life Outcomes. Caregiver Burden Outcomes. Neuroimaging Outcomes. Additional Lessons From Trials in Vascular Dementia. Additional Lessons From Trials In Dementia With Lewy Bodies. Lessons From Trials To Prevent Dementia. Herbal Treatments for Dementia. Lessons from Trials of Psychoactive Compounds in Alzheimer's Disease. Lessons from Non-Pharmacologic and Psychosocial Interventions for Patients with Dementia. Lessons from Psychosocial Interventions Aimed at Caregivers of People with Dementia. Lessons from Trials in Mild Cognitive Impairment. Pharmacoeconomic Outcomes. Executive Dysfunction in Dementia. Ethical Issues. Conclusions.

Kenneth Rockwood MD MPA FRCPC is Professor, Division of Geriatric Medicine, Department of Medicine and Kathryn Allen Weldon Professor of Alzheimer Research, Dalhousie University, Halifax NS, Canada. Serge Gauthier MD FRCPC is Professor and Director of the Alzheimer’s Disease Research Unit, The McGill Centre for Studies in Aging (Le Centre McGill D’Études sur le Vieillissement), Douglas Hospital, Montréal PQ, Canada.

"…a thorough and thoughtful examination of a complex area….a milestone in describing the playing field upon which drug trials of Alzheimer's disease should be conducted. It is a testament to how all the measures used to diagnose Alzheimer's disease do not equally gauge the progression of the disease. Alzheimer's disease is not monolithic, but varies greatly from stage to stage. This book promotes new ways of approaching this aspect of the disease."-Doody's Reviews

• Introduction. The History of Therapeutic Trials in Dementia. Therapeutic Strategies. Treatment Hypotheses. Clinical Trial Designs & Selection of Primary vs.Secondary Endpoints. Qualitative Analyses of Disease Treatment Effects. Inclusion and Exclusion Criteria. Global Outcomes. Cognitive Outcomes. Functional Outcomes. Behavioral Outcomes In Trials Of Cognitive Agents. Quality of Life Outcomes. Caregiver Burden Outcomes. Neuroimaging Outcomes. Additional Lessons From Trials in Vascular Dementia. Additional Lessons From Trials In Dementia With Lewy Bodies. Lessons From Trials To Prevent Dementia. Herbal Treatments for Dementia. Lessons from Trials of Psychoactive Compounds in Alzheimer's Disease. Lessons from Non-Pharmacologic and Psychosocial Interventions for Patients with Dementia. Lessons from Psychosocial Interventions Aimed at Caregivers of People with Dementia. Lessons from Trials in Mild Cognitive Impairment. Pharmacoeconomic Outcomes. Executive Dysfunction in Dementia. Ethical Issues. Conclusions.